Another AFR article, page-385

First 385 Last

Share
Profile

Follow
Thanky

2,519 Posts.

237

03/03/18

08:27

Post #: 31497793
Share

Originally posted by 5hareholder ↑

The bit I can't get my head around is: if this was a scam, then why were people happy to get paid in equity rather than cash? And why were they happy to hold on to that equity? So many of those on the "inside" that had equity are still holding.

Sales teams are ruthless. Management drive a hard line. Sophisticated investors supported the company. None of that is particularly odd. The AFR article could paint dozens of other sales executives in the same light.

And just on the sponsorship...

If last quarter's sales were largely sponsored ($18m approx), then that is 90% of the sponsorship cap. But then how did they generate receipts in the previous 2-3 quarter's of high growth. Either a vast majority of the prior 3x quarter's were not sponsored, or indeed they were also a high percentage of sponsored receipts, and they've successfully integrated clients through the financing facility and they've settled with full payment.

Is anyone else perplexed by that? If the vast majority of the sponsorship pool was used in the past quarter, then were previous sales largely organic, or were they also sponsored and clients have settled to provide room in the pool for subsequent clients?

Either there's plenty of clients out there that will sign up on their own accord, or there's plenty of clients that will pay their dues via the sponsorship, otherwise BIG would not have been able to utilise 90% of the sponsorship pool last quarter.

Expand

It is very perplexing. This has much further to go to get to the bottom of what went on.

FC received monthly financials and should have had full visibility of signups and drawdowns with their Finstro product at the end of the sales process too. It wasn't BIG financing their customers with their own money and no outside involvement.

BIG Price at posting: $2.22 Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 516 more messages in this thread...

First 385 Last

Add BIG (ASX) to my watchlist

Another AFR article, page-385

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News